Publication | Open Access
O-GlcNAcylation: A New Cancer Hallmark?
260
Citations
90
References
2013
Year
Chemoprevention StrategyGlycobiologyMetabolic RemodelingCancer BiologyTumor BiologyOvarian CancerCancer Cell BiologyAnti-cancer AgentCancer MetabolismHuman MetabolismCancer ResearchGlycosylationBiochemistryOncogenic AgentPharmacologyChromatin DynamicsBiomolecular EngineeringDna Methylation EnzymesO-linked N-acetylglucosaminylationNew Cancer HallmarkMetabolismMedicine
O-linked N-acetylglucosaminylation (O-GlcNAcylation) is a reversible post-translational modification consisting in the addition of a sugar moiety to serine/threonine residues of cytosolic or nuclear proteins. Catalyzed by O-GlcNAc-transferase (OGT) and removed by O-GlcNAcase, this dynamic modification is dependent on environmental glucose concentration. O-GlcNAcylation regulates the activities of a wide panel of proteins involved in almost all aspects of cell biology. As a nutrient sensor, O-GlcNAcylation can relay the effects of excessive nutritional intake, an important cancer risk factor, on protein activities and cellular functions. Indeed, O-GlcNAcylation has been shown to play a significant role in cancer development through different mechanisms. O-GlcNAcylation and OGT levels are increased in different cancers (breast, prostate, colon…) and vary during cell cycle progression. Modulating their expression or activity can alter cancer cell proliferation and/or invasion. Interestingly, major oncogenic factors have been shown to be directly O-GlcNAcylated (p53, MYC, NFκB, β-catenin…). Furthermore, chromatin dynamics is modulated by O-GlcNAc. DNA methylation enzymes of the Tet family, involved epigenetic alterations associated with cancer, were recently found to interact with and target OGT to multi-molecular chromatin-remodeling complexes. Consistently, histones are subjected to O-GlcNAc modifications which regulate their function. Increasing number of evidences point out the central involvement of O-GlcNAcylation in tumorigenesis, justifying the attention received as a potential new approach for cancer treatment. However, comprehension of the underlying mechanism remains at its beginnings. Future challenge will be to address directly the role of O-GlcNAc-modified residues in oncogenic-related proteins to eventually propose novel strategies to alter cancer development and/or progression.
| Year | Citations | |
|---|---|---|
2024 | 23.8K | |
2024 | 4.1K | |
2011 | 3.3K | |
2004 | 2.4K | |
2009 | 2.2K | |
1971 | 1.5K | |
2012 | 669 | |
2002 | 658 | |
2008 | 616 | |
2008 | 588 |
Page 1
Page 1